Jim Simons Lineage Cell Therapeutics, Inc. Transaction History

Renaissance Technologies LLC

$63.1 Billion
Q3 2024

A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Lineage Cell Therapeutics, Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 197,100 shares of LCTX stock, worth $98,550. This represents 0.0% of its overall portfolio holdings.

Number of Shares

197,100

Previous 583,622 66.23%

Holding current value

$98,550

Previous $583,000 69.3%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$0.8 - $1.12 $309,217 - $432,904	-386,522 Reduced 66.23%	197,100 $179,000
Q2 2024 Aug 09, 2024	BUY	$0.89 - $1.47 $47,189 - $77,942	53,022 Added 9.99%	583,622 $583,000
Q1 2024 May 13, 2024	BUY	$0.86 - $1.48 $327,316 - $563,288	380,600 Added 253.73%	530,600 $785,000
Q4 2023 Feb 13, 2024	BUY	$0.91 - $1.35 $82,173 - $121,905	90,300 Added 151.26%	150,000 $164,000
Q3 2023 Nov 14, 2023	BUY	$1.16 - $1.53 $4,408 - $5,814	3,800 Added 6.8%	59,700 $70,000
Q2 2023 Aug 11, 2023	BUY	$1.26 - $1.53 $70,434 - $85,527	55,900 New	55,900 $79,000
Q1 2021 May 13, 2021	SELL	$1.77 - $3.1 $40,710 - $71,300	-23,000 Closed	0 $0
Q4 2020 Feb 10, 2021	SELL	$0.95 - $1.83 $415,915 - $801,184	-437,806 Reduced 95.01%	23,000 $40,000
Q3 2020 Nov 13, 2020	SELL	$0.75 - $1.09 $23,170 - $33,674	-30,894 Reduced 6.28%	460,806 $432,000
Q2 2020 Aug 13, 2020	BUY	$0.71 - $1.18 $158,543 - $263,494	223,300 Added 83.2%	491,700 $428,000
Q1 2020 May 14, 2020	BUY	$0.6 - $1.58 $161,040 - $424,072	268,400 New	268,400 $222,000

Others Institutions Holding LCTX

# of Institutions

121

Shares Held

94.2M

Call Options Held

63.8K

Put Options Held

View Full List

About Lineage Cell Therapeutics, Inc.

Ticker LCTX
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 169,755,008
Market Cap $84.9M
Description
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...

More about LCTX

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account